May 13, 2020
Dr. Santanu Datta is the CSO of
Bugworks, Inc., and has been working in the field of infectious
disease for decades. He begins telling listeners about the
antibiotic development, highlighting the difference it has
He explains why it has been difficult to develop new antibiotics from both a market and scientific perspective. He also explains the mechanisms of antibiotic and bacteria interaction, from the parts the antibiotics have traditionally targeted to the types of adaptations and evolutions bacteria are able to make to impede antibiotics, resulting in antibiotic resistance.
He then talks about his
company's work to make a new broad spectrum antibiotic that targets
the most dangerous bacteria hospitals face in one
antibiotic, from E. coli to Staphylococcus aureus to other common bacteria in hospital patients.
Therefore, doctors may use this in an IV form when they don't have
time to wait for test results because of the health risks to the
Dr. Datta explains that his new generation antibiotic targets two parts of the bacteria at once, limiting its ability to escape unharmed. One of the targets includes the enzyme bacteria require for replication. He also explains their approval process as they head towards phase 1 and adds that they are funded by Carb-x.
For more, see the company's web site at https://bugworksresearch.com/